Search
Hydrocortisone acetate
go.drugbank.com/drugs/DB14539ApprovedInvestigationalVet approvedCategories: Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP3A InducersHydrocortisone valerate
go.drugbank.com/drugs/DB14544ApprovedVet approvedCategories: Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 CYP3A InducersEdetate disodium anhydrous
go.drugbank.com/drugs/DB14600ApprovedInvestigationalVet approvedEdetate disodium anhydrous is a polyvalent chelating agent used to treat hypercalcemia and digitalis toxicity associated ventricular arrhythmias.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsPrednisolone phosphate
go.drugbank.com/drugs/DB14631ApprovedInvestigationalVet approvedPrednisolone phosphate is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone phosphate was granted FDA Approval on 19 December 1973.
Categories: Cytochrome P-450 CYP2A6 Inducers, P-glycoprotein inducersLarotrectinib
go.drugbank.com/drugs/DB14723ApprovedInvestigationalLarotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell gr...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesFilgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigationalRheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases. The disease is associated with extra-articular manifestations, prog...
Categories: P-glycoprotein substratesOliceridine
go.drugbank.com/drugs/DB14881ApprovedInvestigationalSevere acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors. Opioid receptors are seven-transmembrane G...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesMavacamten
go.drugbank.com/drugs/DB14921ApprovedInvestigationalMavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is ...
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP2C19 InducersUmbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawnMarginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with rituximab (an anti-CD20 drug), either alone or in combination with chemotherapy. Unfortunately, many patients experience a relapse o...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsBrepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigationalBrepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults. It inhibits TYK2- and JAK1-mediated cytokine signaling, blocking phosphorylation of signal transducers and activat...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors